Clinics and research in hepatology and gastroenterology最新文献

{"title":"Immune-mediated liver injury induced by PD-1/PD-L1 inhibitors differs from idiosyncratic drug-induced liver injury.","authors":"Yu Su, Yao Meng, Mengmeng Zhang, Tiantian Guo, Mengyu Zhao, Liwei Liu, Wei Chen, Jidong Jia, Yan Wang, Xinyan Zhao","doi":"10.1016/j.clinre.2026.102938","DOIUrl":"https://doi.org/10.1016/j.clinre.2026.102938","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to compare the clinical characteristics, pathology, and outcomes of ILICI and iDILI.</p><p><strong>Methods: </strong>In this single-center retrospective study, clinical, laboratory, imaging, pathological, and outcome data from patients diagnosed with ILICI or iDILI were analyzed.</p><p><strong>Results: </strong>A total of 71 ILICI and 305 iDILI cases were included. Compared with the iDILI cohort, patients with ILICI were older (median age 66.0 vs. 56.0 years, P < 0.001). The ILICI group exhibited longer latency, a higher proportion of cholestatic and mixed liver injury patterns, and less severe biochemical abnormalities, with lower ALT, AST, and total bilirubin levels (P < 0.001). Imaging revealed less frequent signs of hepatic inflammation in ILICI (P < 0.05). Histologically, ILICI appeared to be associated with cholestatic features. Among patients with hepatocellular injury pattern, the cumulative rate of ALT normalization was significantly higher in the ILICI group (HR: 3.677, P < 0.001).</p><p><strong>Conclusions: </strong>Our study revealed that, compared with patients with iDILI, the patients with ILICI may present with a higher proportion of the cholestatic biochemical pattern. Furthermore, hepatocellular ILICI showed a trend toward more rapid biochemical recovery compared with hepatocellular iDILI.</p>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":" ","pages":"102938"},"PeriodicalIF":2.6,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive assessment of hepatic steatosis in Wilson Disease: An international registry-based study.","authors":"Frederik Teicher Lauridsen Kirk, Asim Ulcay, Hatice Maras, Sefa Keserci, Alba Diaz, Kaitlin Maciejewski, Regino González-Peralta, Rima Fawaz, Sanjiv Harpavat, Uyen Kim To, Sabela Lens, María-Carlota Londoño, Yanhong Deng, Thomas Damgaard Sandahl, Michael L Schilsky, Zoe Mariño","doi":"10.1016/j.clinre.2026.102933","DOIUrl":"https://doi.org/10.1016/j.clinre.2026.102933","url":null,"abstract":"<p><strong>Background: </strong>Hepatic steatosis is an early histological feature of Wilson Disease (WD) with unknown clinical significance. Non-invasive tests (NITs) for steatosis are increasingly used, despite a lack of data supporting their utility in WD.</p><p><strong>Methods: </strong>International registry study including adults and children with WD, histological hepatic steatosis grading, and available NITs [hepatic steatosis index (HSI) or controlled attenuation parameter (CAP)]. NITs were tested against liver biopsy (LB) to detect moderate-to-severe steatosis (MSSt), and WD-specific cut-offs were developed. The analysis focused on patients with ≤1 year between NITs and LB.</p><p><strong>Results: </strong>103 patients with WD and histological steatosis grading were included, with 57 evaluated at diagnosis. Overall, MSSt was present in 35.9%. NITs were measured ≤1 year from LB in 59 (57.3%); Among those, CAP, but not HSI, was significantly elevated in MSSt and increased with histologic steatosis grade (p=0.0017). Similarly, CAP showed excellent accuracy for detecting MSSt in WD (AUROC=0.93 (0.83, 1.00) vs only 0.64 (0.44, 0.84) for HSI). An optimized CAP cut-off of ≥291 dB/m resulted in a sensitivity of 0.78 (0.40, 0.97) and specificity of 1.00 (0.81, 1.00). Additionally, an exploratory combined score of CAP & ALT further improved MSSt detection (AUROC=0.96 (0.88, 1.00)).</p><p><strong>Conclusions: </strong>MSSt is common in WD, and CAP showed promising diagnostic performance for detecting MSSt in WD at diagnosis and at follow-up. Future studies are needed to determine the potential clinical and prognostic significance of MSSt in WD. This study also highlights the need for assessing NITs and their cut-offs in rare hepatic storage disorders.</p>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":" ","pages":"102933"},"PeriodicalIF":2.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed mortality after successful hemostasis in cirrhotic upper gastrointestinal bleeding: A prospective observational study","authors":"Nourhan Badwei,&nbsp;Runia Fouad El-Folly,&nbsp;Hazem Ahmed Abdu Hemdan,&nbsp;Ghada Ossama Mohamed Wassif,&nbsp;Walaa Ahmed Yousry Kabiel,&nbsp;Mohammed Abozaid Marzouk Biomy","doi":"10.1016/j.clinre.2026.102886","DOIUrl":"10.1016/j.clinre.2026.102886","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 7","pages":"Article 102886"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative analysis of genetic and cellular interactions connecting inflammatory bowel disease and primary biliary cholangitis","authors":"Zhenan Chen,&nbsp;Weiquan Zhu,&nbsp;Guang Liu,&nbsp;Baolei Yu","doi":"10.1016/j.clinre.2026.102885","DOIUrl":"10.1016/j.clinre.2026.102885","url":null,"abstract":"<div><h3>Background</h3><div>Inflammatory bowel disease (IBD) and primary biliary cholangitis (PBC) have been reported to coexist in some patients, but the extent of this association remains to be further clarified. Clarifying their shared genetic architecture and intercellular interaction patterns may provide insight into the biological links between these two immune-mediated diseases and inform future disease monitoring strategies.</div></div><div><h3>Methods</h3><div>This study integrated summary statistics from genome-wide association studies (GWAS) of two independent IBD cohorts and one PBC cohort, along with spatially resolved single-cell transcriptomic data. Genetic correlations were examined using linkage disequilibrium score regression, genetic covariance estimation, and localized variant association analyses. Shared susceptibility loci were identified through conditional/joint false discovery rate (FDR) approaches and multi-trait joint analysis. Furthermore, a genetic information–guided cell-type spatial mapping strategy was applied to delineate disease-associated cellular populations at single-cell resolution.</div></div><div><h3>Results</h3><div>Genetic analyses revealed significant genome-wide correlations and extensive polygenic overlap between IBD, its subtypes, and PBC. Local variation analyses further identified multiple chromosomal regions exhibiting regional genetic associations shared by both diseases. Several putative shared susceptibility loci were discovered, with a subset validated using independent datasets. The genetic information–guided spatial mapping approach demonstrated comparable tissue-resident cell distribution patterns between IBD and PBC.</div></div><div><h3>Conclusion</h3><div>By integrating GWAS data with single-cell transcriptomic profiling, this study provides a systematic characterization of the genetic relationships between IBD and PBC. These findings offer genetic and cellular-level insights that contribute to a deeper understanding of the molecular basis underlying their comorbidity.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 7","pages":"Article 102885"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality trends and disparities for the six leading causes of cancer death among individuals aged 15–45 years in the United States, 1999–2023","authors":"Huanyong Tian,&nbsp;Yangjie Liu,&nbsp;Xia Chen,&nbsp;Tian Lv,&nbsp;Anwei Wu","doi":"10.1016/j.clinre.2026.102881","DOIUrl":"10.1016/j.clinre.2026.102881","url":null,"abstract":"<div><h3>Background</h3><div>Cancer mortality among individuals aged 15–45 years is a critical metric for assessing progress in cancer control. This study examined long-term mortality trends and sociodemographic disparities for the six leading causes of cancer death among individuals aged 15–45 years in the United States from 1999 to 2023.</div></div><div><h3>Methods</h3><div>Mortality data were obtained from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database (1999–2023). Death records for individuals aged 15–45, with any of the six cancers listed as the underlying cause, were included. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Temporal trends were analyzed using Joinpoint regression to compute the average annual percent change (AAPC) and 95% confidence interval (CI). Future mortality through 2035 was projected using autoregressive integrated moving average (ARIMA) modeling.</div></div><div><h3>Results</h3><div>Between 1999 and 2023, Lung cancer mortality declined most sharply (AAPC: –4.79*; 95% CI: –5.45 to –4.13). Breast cancer mortality also exhibited a significant decrease. In contrast, colorectal cancer (CRC) mortality increased significantly (AAPC: 0.88*; 95% CI: 0.72 to 1.04), emerging as the only major cancer with a sustained upward trajectory in this age group. Mortality from leukemia, brain cancer, and cervical cancer remained stable or declined modestly. Pronounced disparities were observed across census regions, racial/ethnic groups, and sex. ARIMA projections indicated that CRC mortality among individuals aged 15–45 years is expected to increase further through 2035, whereas mortality from lung cancer and breast cancer is projected to continue declining.</div></div><div><h3>Conclusion</h3><div>Substantial reductions in lung cancer mortality among individuals aged 15–45 years in the United States have been offset by a concerning rise in colorectal cancer mortality in this age group. Strategic shifts toward risk-stratified screening, equitable care, and targeted interventions are imperative.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 7","pages":"Article 102881"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148381769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TACE-induced liver injury in hepatocellular carcinoma: mechanisms, prediction, and prevention in the era of gut microbiota and inflammasome research","authors":"Kai Sun,&nbsp;Qiuge Gao,&nbsp;Chengzhi Zhang,&nbsp;Huanzhang Niu","doi":"10.1016/j.clinre.2026.102874","DOIUrl":"10.1016/j.clinre.2026.102874","url":null,"abstract":"<div><div>Transarterial chemoembolization (TACE) is a cornerstone locoregional therapy for hepatocellular carcinoma (HCC), yet most candidates also have cirrhosis. That makes TACE a balancing act: controlling tumor progression while protecting a liver with limited functional reserve, often over multiple sessions. This narrative review synthesizes current evidence on TACE-induced liver injury (TACE-LI), with emphasis on its definitions, mechanisms, risk prediction, and prevention, and further contextualizes emerging data on the gut-liver axis and inflammasome signaling. Clinically, TACE-LI spans a spectrum from transient biochemical worsening and post-embolization syndrome (PES; fever, pain, malaise) to clinically meaningful decompensation and post-TACE liver failure (PTLF). A key challenge is that the literature uses heterogeneous definitions and thresholds for both TACE-LI and PTLF, complicating comparisons between studies and weakening clarity around retreatment decisions. Mechanistically, injury is multifactorial: arterial ischemia from embolization, ischemia-reperfusion and oxidative stress, local chemotherapeutic toxicity and material retention, biliary or microvascular injury, and a systemic inflammatory response that can drive both symptoms and laboratory derangement. Our review also highlights how cirrhosis-associated gut barrier dysfunction may prime inflammatory cascades through dysbiosis, bacterial translocation, and endotoxin signaling (e.g., LPS–TLR4), potentially shaping vulnerability after embolization. In this context, inflammasome pathways, especially NLRP3, are discussed as amplifiers that translate danger signals (DAMPs), reactive oxygen species, and microbial cues into IL-1β/IL-18 release and pyroptotic injury, linking sterile ischemic damage to immune activation. For risk stratification, baseline hepatic reserve (Child–Pugh, ALBI), tumor burden, and technical intensity remain central, and dynamic indicators such as post-TACE ALBI deterioration help capture clinically relevant trajectories. Our review also summarizes predictive tools such as nomograms and models for complications (including PES), and notes ongoing exploration of machine-learning–assisted decision support. Prevention ultimately rests on careful patient selection, liver-sparing technique (including superselective approaches when feasible), and structured peri‑procedural care to mitigate PES and reduce infectious or biliary complications.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 7","pages":"Article 102874"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148338111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib for advanced hepatocellular carcinoma: A retrospective clinical analysis","authors":"Ruijun Ren,&nbsp;Zexin Wang","doi":"10.1016/j.clinre.2026.102880","DOIUrl":"10.1016/j.clinre.2026.102880","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and remains a major cause of cancer-related mortality worldwide. This study aimed to evaluate the safety and efficacy of hepatic artery infusion chemotherapy (HAIC) combined with camrelizumab and apatinib in patients with advanced HCC. A retrospective analysis was conducted on patients with advanced HCC who received either camrelizumab plus apatinib (n = 65) or HAIC combined with camrelizumab and apatinib (n = 65). Objective response rate (ORR), disease control rate (DCR), serum tumor marker levels, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and carbohydrate antigen 19–9 (CA19–9), adverse events, progression-free survival (PFS), and overall survival (OS) were compared between the two groups. Baseline clinical characteristics were comparable between the two groups. Compared with camrelizumab plus apatinib alone, treatment with HAIC combined with camrelizumab and apatinib achieved significantly higher ORR and DCR and was associated with more favorable post-treatment serum AFP, CEA, and CA19–9 levels. Treatment-related adverse events were generally manageable. At the final follow-up, median PFS was 15 (2–24) months in the camrelizumab plus apatinib group and 15 (8–30) months in the HAIC plus camrelizumab plus apatinib group, respectively. Median OS of the two groups was 20 (6–27) months and 21 (10–30) months, respectively. Based on the Kaplan-Meier analysis, patients receiving the trimodality therapy demonstrated significantly prolonged PFS and OS. Together, HAIC combined with camrelizumab and apatinib demonstrated favorable efficacy and acceptable safety in patients with advanced HCC. This combination regimen may represent a promising therapeutic strategy for advanced HCC.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 7","pages":"Article 102880"},"PeriodicalIF":2.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148367280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of severe acute alcoholic hepatitis in France: results of a national survey: R1","authors":"J.F.D. Cadranel ,&nbsp;H.T. Zougmoré ,&nbsp;T. Thévenot ,&nbsp;T. Dao ,&nbsp;J.-B. Nousbaum ,&nbsp;M. Rudler ,&nbsp;N. Carbonell ,&nbsp;A. Abergel ,&nbsp;A. Coilly ,&nbsp;K. Bideau ,&nbsp;E. Nguyen-Khac ,&nbsp;P. Mathurin ,&nbsp;C. Barrault ,&nbsp;T. Paupard ,&nbsp;P. Sogni ,&nbsp;F. Durand ,&nbsp;C. Lemaitre ,&nbsp;V. de Lédinghen ,&nbsp;F. Heluwaert ,&nbsp;J.-P. Richardet ,&nbsp;P. Pulwermacher","doi":"10.1016/j.clinre.2026.102848","DOIUrl":"10.1016/j.clinre.2026.102848","url":null,"abstract":"<div><div>Since 2010, little data have been available in France on the management of severe acute alcoholic hepatitis (sAH). In order to obtain a current \"mapping\" of the management of sAH in France, a practice survey was conducted from 04/2022 to 07/2023.</div><div>A Google questionnaire pre-established by a working group was sent to all the hepatogastroenterology departments of general hospitals (nUH) and hepatology departments of university hospitals (UH). The results are expressed as means ± SD. The data included demographics, number of sAH treated per centre with corticosteroids (C) or N-acetylcysteine (NAC) combined with C, existence of an sAH treatment protocol, systematic use of transjugular liver biopsy (LB) and treatment modalities. Treatment: use of C alone or C -NAC.</div><div>A total of 457 physicians responded (R): mean age 40 years (12.5); UH 53.3%, nUH 46.7%, hepatologists 57%, gastroenterologists 39%, juniors 21%. The number of sAH cases treated with C or C<img>NAC per center was 25 (0 to 300); this number was higher in UH than in nUH: 34 (29) vs nUH 15.4 (13.4), p &lt; 0.001. A treatment protocol existed in 62% of UH vs 42% of nUH, p &lt; 0.001. LB was systematically performed in 98% of UH vs 50% of others, p &lt; 0.001. The time to obtain LB was 3.4 days (UH) vs 4.9 days (nUH), p &lt; 0.001. 83% of respondents waited 4 days (2–6) before starting treatment in the event of a documented bacterial infection. The treatment administered was: C alone in 70% of patients (UH vs nUH,ns), NAC use: UH 40% vs nUH 47.3% (ns).</div><div>70% of respondents were responsible for initiating treatment (65% in UH vs 72% in nUH (p &lt; 0.01). The treatment was much more often initiated by senior doctors (80.6%vs 20.4% junior doctors,p &lt; 0.001). 62% of respondents used preemptive treatment before corticosteroid treatment in the event of a positive HBs antigen; 59.4% in UH vs 65% in nUH (p = 0.004) . 76% performed an upper gastrointestinal endoscopy if none had been previously performed (77% in UH vs 75% in nUH,ns).</div><div>The results of this national practice study,carried out in a large sample of doctors practising in university and non -university hospitals show a disparity in the use of LB in cases of suspected sAH, since 50% of respondents outside university hospitals do not use LB, mainly due to the lack of local availability. Dual C<img>NAC therapy is used fairly frequently.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 6","pages":"Article 102848"},"PeriodicalIF":2.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on ‘clinical characteristics and risk factors of drug-induced hepatotoxicity in cancer patients following repeated chemotherapy cycles’","authors":"Kishankumar Mahida ,&nbsp;Snehal Rajendra Jagtap","doi":"10.1016/j.clinre.2026.102779","DOIUrl":"10.1016/j.clinre.2026.102779","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102779"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146123871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age and sex differences in intrapancreatic fat deposition: A cross-sectional CT study","authors":"Yiping Zhang,&nbsp;Dingzhe Zhang,&nbsp;Rongzhou Wang,&nbsp;Rui Yu,&nbsp;Yu Wang,&nbsp;Jianhua Wang,&nbsp;Xiao Chen","doi":"10.1016/j.clinre.2026.102770","DOIUrl":"10.1016/j.clinre.2026.102770","url":null,"abstract":"<div><h3>Background/aims</h3><div>Intra-pancreatic fat deposition (IPFD) is associated with health issues, yet its distribution patterns across age and gender remain unclear. This study analyzed differences in computed tomography (CT)-based IPFD content among different age and gender groups.</div></div><div><h3>Methods</h3><div>A retrospective cohort of 1305 adults undergoing chest CT examinations was established. Pancreatic and splenic CT attenuation values were measured, pancreas-to-spleen CT ratio (P/S) and pancreas-to-spleen CT difference (P-S) were also calculated which served as indicators of IPFD. Pearson correlation analysis was employed to assess the relationship between each parameter and age stratified by sex. Multiple linear regression was applied to evaluate the independent effects of age and sex.</div></div><div><h3>Results</h3><div>Pancreatic fat-related CT parameters were negatively correlated with age (<em>r</em> = -0.527 to -0.467, <em>p</em> &lt; 0.001). Compared to young adults aged 21–29 years, pancreatic CT attenuation and both the P/S ratio and P-S difference fallen markedly by the 51–59-year group. An even greater difference was observed in individuals over 70 years of age. The P/S ratio and P-S of males were significantly lower than female in each age group. Multiple linear regression showed that age were independent negative predictors of all parameters (<em>p</em> &lt; 0.001), while gender was an independent influencing factor of the P/S ratio (β = 0.073, <em>p</em> = 0.004) and P-S (β = 0.072, <em>P</em> = 0.004), but had no independent predictive effect on the unadjusted pancreatic CT value.</div></div><div><h3>Conclusion</h3><div>IPFD shows a gradual increase with advancing age and is higher in males compared to females.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"50 3","pages":"Article 102770"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}